HAVCR2 and neoplasm: As has been reported previously, treatment with anti-PD-1 agents may induce the expression of other checkpoint molecules, such as TIM-3 and LAG3, and dual-blockade of PD-1/TIM-3 or PD-1/LAG3 has been shown to enhance the anti-tumour response77,78.